In the past decade, two events have sent shockwaves through the diagnostics industry: Theranos and Covid. The first, is a parable against faking it in an industry which rightly prizes accuracy and safety. The second was an almost insatiable demand for diagnostic testing kits, where the speed of information took second place to accuracy. Was Elizabeth Holmes onto something when she founded Theranos? What if her devices had been able to live up to the hype? And what reputation does self-testing now have in the diagnostics industry? In this episode of Invent Life Sciences, we take a look at the Theranos story and the Covid pandemic and see what lessons can be learned from each.
Find out more on this week’s episode of Invent: Life Sciences from TTP.
This Week’s Guests
Professor Tony Cass
Tony is a professor of chemical biology at Imperial College London, an institution he has been a part of for the best part of three decades. Alongside his fellowship of the Royal Society of Chemistry, Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors, and his work in this area led to the development of the first electronic blood glucose measuring system.
Dr. Giles Sanders
Giles is the head of In Vitro diagnostics at TTP and has been with us for two decades. During that time he has been influential in the development of numerous diagnostics systems that have been successfully placed on the market. He works across all aspects of In Vitro diagnostics, from automated central lab, to point of care and home use devices.
